(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 39.23% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.01%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.19%.
Harrow's revenue in 2026 is $272,303,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $13,472,685,645, with the lowest HROW revenue forecast at $12,809,996,896, and the highest HROW revenue forecast at $14,228,448,657. On average, 9 Wall Street analysts forecast HROW's revenue for 2027 to be $20,009,849,546, with the lowest HROW revenue forecast at $17,476,368,121, and the highest HROW revenue forecast at $22,536,257,328.
In 2028, HROW is forecast to generate $27,607,687,743 in revenue, with the lowest revenue forecast at $24,340,036,535 and the highest revenue forecast at $30,760,671,459.